Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Equity Average (2021 - 2025)

Historic Equity Average for Maxcyte (MXCT) over the last 5 years, with Q3 2025 value amounting to $185.5 million.

  • Maxcyte's Equity Average fell 1462.73% to $185.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.5 million, marking a year-over-year decrease of 1462.73%. This contributed to the annual value of $219.2 million for FY2024, which is 981.56% down from last year.
  • Latest data reveals that Maxcyte reported Equity Average of $185.5 million as of Q3 2025, which was down 1462.73% from $195.1 million recorded in Q2 2025.
  • Over the past 5 years, Maxcyte's Equity Average peaked at $263.5 million during Q4 2021, and registered a low of $171.5 million during Q3 2021.
  • For the 5-year period, Maxcyte's Equity Average averaged around $229.2 million, with its median value being $232.8 million (2023).
  • In the last 5 years, Maxcyte's Equity Average skyrocketed by 4919.79% in 2022 and then crashed by 1462.73% in 2025.
  • Maxcyte's Equity Average (Quarter) stood at $263.5 million in 2021, then dropped by 3.53% to $254.2 million in 2022, then fell by 8.43% to $232.8 million in 2023, then dropped by 9.88% to $209.8 million in 2024, then decreased by 11.57% to $185.5 million in 2025.
  • Its Equity Average was $185.5 million in Q3 2025, compared to $195.1 million in Q2 2025 and $202.8 million in Q1 2025.